RenuTend RSS Authorised This medicine is authorised for use in the European Union tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells Medicine Veterinary Authorised
Page contentsPage contents Overview Product details Authorisation details Assessment history News on RenuTend More information on RenuTend Application under evaluation CVMP opinion European Commission decision OverviewUp-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website Product details Name of medicine RenuTend Active substance tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells International non-proprietary name (INN) or common name tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells Pharmacotherapeutic groupMusculo-skeletal systemOther drugs for disorders of the musculo-skeletal system Authorisation details EMA product number EMEA/V/C/005428 Assessment history Initial marketing authorisation documents CVMP summary of positive opinion for RenuTendAdopted Reference Number: EMA/CVMP/73401/2022 English (EN) (131.59 KB - PDF)First published: 21/02/2022 View News on RenuTend Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 9-10 September 202512/09/2025 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 November 202408/11/2024 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 December 202308/12/2023 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 11-13 July 202314/07/2023 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 15-16 February 202221/02/2022 More information on RenuTend Arti-Cell Forte / RenuTend - direct animal healthcare professional communication (DaHPC) This page was last updated on 21/02/2022 Share this page